Boger family trusts boost CervoMed (CRVO) stake with 955K-unit private deal
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
CervoMed Inc. director-associated trusts participated in a significant private placement. On June 11, 2026, the Joshua S. Boger 2021 Trust purchased 955,414 units at $3.14 per unit in a private placement, each unit consisting of one share of common stock plus one Series B warrant and one Series C warrant.
The Series B warrants have a $3.32 exercise price and expire five years from issuance, while the Series C warrants have a $3.14 exercise price and expire one year from issuance. After these transactions, trusts for which Joshua S. Boger is sole trustee hold 1,600,117 and 195,748 common shares, respectively, though he disclaims beneficial ownership of these securities.
Positive
- None.
Negative
- None.
Insights
Director-linked trusts bought 955,414 CervoMed units with attached warrants in a private placement.
CervoMed Inc. completed a private placement where the JSB 2021 Trust, tied to director and 10% owner Joshua S. Boger, acquired 955,414 units at $3.14 each. Every unit includes one common share plus a Series B and Series C warrant, increasing indirect exposure to the stock and future optionality.
The Series B warrants carry a $3.32 exercise price and a five-year term from June 11, 2026, while Series C warrants have a $3.14 exercise price and a one-year term. Warrant terms include a 19.99% ownership cap, limiting exercises that would push the trust above that threshold.
Following the deals, trusts for which Boger is sole trustee hold 1,600,117 and 195,748 common shares. He formally disclaims beneficial ownership for Section 16 purposes. The filing does not show derivative positions beyond these newly acquired warrants, so future company disclosures will frame how and when these instruments are exercised within the ownership cap mechanics.
Insider Trade Summary
Net Buyer: 2,866,242 shares ($3,000,000)
Net Buy
4 txns
Insider
BOGER JOSHUA S
Role
null
Bought
2,866,242 shs ($3.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Series B Warrants | 955,414 | $0.00 | -- |
| Purchase | Series C Warrants | 955,414 | $0.00 | -- |
| Purchase | Common Stock | 955,414 | $3.14 | $3.00M |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Series B Warrants — 955,414 shares (Indirect, By Trust);
Series C Warrants — 955,414 shares (Indirect, By Trust);
Common Stock — 1,795,865 shares (Indirect, By Trusts);
Common Stock — 216,817 shares (Direct, null)
Footnotes (1)
- On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit. After giving effect to all transactions described herein, consists of (i) 1,600,117 shares of the Issuer's common stock held by the JSB 2021 Trust and (ii) 195,748 shares of the Issuer's common stock held by The Amy S. Boger 2021 Trust (the "ASB 2021 Trust"). The Reporting Person serves as the sole trustee of each of the JSB 2021 Trust and the ASB 2021 Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. The Series B Warrants have an exercise price equal to $3.32 per share of Common Stock or $3.319 per pre-funded warrant, are exercisable immediately, and will expire five years from the issuance date of the Series B Warrant. The Series C Warrants have an exercise price equal to $3.14 per share of Common Stock or $3.139 per pre-funded warrant, are exercisable immediately, and will expire one year from the issuance date of the Series C Warrant. Under the terms of the Series B Warrants and the Series C Warrants, the Issuer may not effect the exercise of any portion thereof, and the JSB 2021 Trust will not have the right to exercise any portion thereof, which, upon giving effect to such exercise, would cause the JSB 2021 Trust (together with its affiliates) to own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. To the extent that exercise of the Series B Warrants or Series C Warrants will result in the JSB 2021 Trust (together with its affiliates) beneficially owning shares of Common Stock above such ownership limitations, the JSB 2021 Trust may exercise its Series B Warrants or Series C Warrants for pre-funded warrants to purchase shares of Common Stock, which pre-funded warrants will include a substantially similar maximum ownership limitation. The Series B Warrants and Series C Warrants are owned by the JSB 2021 Trust.
Key Figures
Units purchased: 955,414 units
Unit purchase price: $3.14 per unit
Series B warrant exercise price: $3.32 per share
+5 more
8 metrics
Units purchased
955,414 units
Private placement on June 11, 2026
Unit purchase price
$3.14 per unit
Price paid by JSB 2021 Trust
Series B warrant exercise price
$3.32 per share
Exercise price for Series B Warrants
Series C warrant exercise price
$3.14 per share
Exercise price for Series C Warrants
Ownership cap
19.99% of outstanding common stock
Maximum beneficial ownership allowed under warrants
JSB 2021 Trust common shares
1,600,117 shares
Common stock held after transactions
ASB 2021 Trust common shares
195,748 shares
Common stock held after transactions
Indirect common shares following transaction
1,795,865 shares
Total common stock held by the two trusts
Key Terms
private placement, securities purchase agreement, Series B Warrants, Series C Warrants, +2 more
6 terms
private placement financial
"On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement..."
A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.
securities purchase agreement financial
"...completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement")..."
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
Series B Warrants financial
"...one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant")..."
Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.
Series C Warrants financial
"...one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant")..."
Series C warrants are tradable certificates issued alongside a later-stage financing round that give the holder the right to buy company shares at a fixed price within a set time window. They matter to investors because they can provide low-cost upside if the company’s share price rises, but they can also dilute existing shareholders when converted, similar to a coupon that lets someone buy concert tickets later at today’s price — good for the coupon holder, changing the crowd size and ticket value for everyone else.
pre-funded warrant financial
"...Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock..."
A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission..."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What did CervoMed (CRVO) disclose in Joshua Boger’s latest Form 4?
CervoMed reported that the Joshua S. Boger 2021 Trust bought 955,414 units in a private placement at $3.14 per unit, each including one common share plus a Series B and Series C warrant, increasing that trust’s indirect economic exposure to the company.
How many CervoMed units were purchased by the JSB 2021 Trust and at what price?
The JSB 2021 Trust purchased 955,414 units at $3.14 per unit. Each unit consists of one CervoMed common share, one Series B warrant and one Series C warrant, giving the trust both immediate equity and additional option-like exposure to future share price movements.
What are the key terms of CervoMed’s Series B and Series C warrants bought in this transaction?
The Series B warrants have a $3.32 exercise price and expire five years from their June 11, 2026 issuance. The Series C warrants have a $3.14 exercise price and expire one year from issuance, both being exercisable immediately under the disclosed warrant terms.
What ownership limitations apply to the CervoMed Series B and Series C warrants?
The warrants include a 19.99% ownership cap. CervoMed cannot effect, and the JSB 2021 Trust cannot request, exercises that would cause it and affiliates to own more than 19.99% of outstanding common stock; excess exposure can instead be taken via pre-funded warrants.
Does Joshua Boger personally own the CervoMed securities reported in this Form 4?
The Form 4 states the common shares and warrants are held by the JSB 2021 Trust and the ASB 2021 Trust. Joshua Boger is sole trustee of both but expressly disclaims beneficial ownership of these securities for Section 16 or any other legal purpose.